SpyGlass Pharma is a biopharmaceutical company developing sustained drug delivery systems for chronic eye conditions, with a focus on glaucoma treatment. The company's lead product, the Bimatoprost Drug Pad-IOL System, combines an FDA-approved glaucoma medication with a drug-loaded intraocular lens implanted during routine cataract surgery to deliver three years of continuous therapy, eliminating the need for daily eye drops. The company generates potential revenue through anticipated Medicare reimbursement for the cataract procedure itself, physician-administered drug coding for the medication component, and incremental revenue opportunities for ambulatory surgery centers, while leveraging an efficient sales model targeting the concentrated cataract surgeon market where existing clinical efficacy and regulatory pathways accelerate commercialization.